JP2022535062A5 - - Google Patents
Info
- Publication number
- JP2022535062A5 JP2022535062A5 JP2021571692A JP2021571692A JP2022535062A5 JP 2022535062 A5 JP2022535062 A5 JP 2022535062A5 JP 2021571692 A JP2021571692 A JP 2021571692A JP 2021571692 A JP2021571692 A JP 2021571692A JP 2022535062 A5 JP2022535062 A5 JP 2022535062A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- composition according
- cancer
- patient
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024195743A JP2025013608A (ja) | 2019-06-03 | 2024-11-08 | Ｇｍ－ｃｓｆ拮抗薬を用いたがんの治療 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962856638P | 2019-06-03 | 2019-06-03 | |
| US62/856,638 | 2019-06-03 | ||
| PCT/US2020/035957 WO2020247521A1 (en) | 2019-06-03 | 2020-06-03 | Treatment of cancers with gm-csf antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024195743A Division JP2025013608A (ja) | 2019-06-03 | 2024-11-08 | Ｇｍ－ｃｓｆ拮抗薬を用いたがんの治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022535062A JP2022535062A (ja) | 2022-08-04 |
| JP2022535062A5 true JP2022535062A5 (https=) | 2023-06-12 |
Family
ID=71842826
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021571692A Pending JP2022535062A (ja) | 2019-06-03 | 2020-06-03 | Ｇｍ－ｃｓｆ拮抗薬を用いたがんの治療 |
| JP2024195743A Pending JP2025013608A (ja) | 2019-06-03 | 2024-11-08 | Ｇｍ－ｃｓｆ拮抗薬を用いたがんの治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024195743A Pending JP2025013608A (ja) | 2019-06-03 | 2024-11-08 | Ｇｍ－ｃｓｆ拮抗薬を用いたがんの治療 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220331425A1 (https=) |
| EP (1) | EP3976080A1 (https=) |
| JP (2) | JP2022535062A (https=) |
| KR (1) | KR20220042067A (https=) |
| CN (2) | CN114599398A (https=) |
| AU (1) | AU2020287327A1 (https=) |
| WO (1) | WO2020247521A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4314037A4 (en) * | 2018-10-31 | 2025-06-04 | Mayo Foundation For Medical Education And Research | Materials and methods for treating cancer |
| WO2022093855A1 (en) * | 2020-10-26 | 2022-05-05 | Kiniksa Pharmaceuticals, Ltd. | Treatment of cancers with gm-csf antagonists |
| CN116685352A (zh) * | 2020-10-26 | 2023-09-01 | 基尼克萨制药有限公司 | 用gm-csf拮抗剂治疗癌症 |
| CN112813066A (zh) * | 2021-01-22 | 2021-05-18 | 中国科学院微生物研究所 | 一种调控Treg细胞活化的方法 |
| WO2023220128A1 (en) * | 2022-05-10 | 2023-11-16 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Targeting myeloid-derived suppressor cells (mdscs) in bladder cancer to enhance efficacy of adoptive cell therapy (act) |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| RU2447085C2 (ru) | 2005-05-18 | 2012-04-10 | МорфоСис АГ | Анти-gm-csf антитела и их применение |
| JP4943044B2 (ja) | 2005-07-20 | 2012-05-30 | リンテック株式会社 | 粘着シート |
| MX2008012291A (es) | 2006-03-27 | 2009-01-12 | Medimmune Ltd | Miembro que enlaza al receptor gm-csf. |
| CA2851322C (en) | 2011-10-10 | 2020-03-31 | Medimmune Limited | Treatment for rheumatoid arthritis with gm csfr alpha antibodies |
| CN106456761A (zh) | 2014-05-19 | 2017-02-22 | 免疫医疗有限公司 | 对类风湿关节炎的治疗 |
| EP3212228B1 (en) * | 2014-10-27 | 2025-12-03 | Ruprecht-Karls-Universität Heidelberg | Maraviroc alone or in combination therapy for the treatment of cancer |
| EP3786293A1 (en) | 2015-06-12 | 2021-03-03 | AxioMx, Inc. | Methods and compositions for producing a chimeric polypeptide |
| GB201519331D0 (en) | 2015-11-02 | 2015-12-16 | Glaxosmithkline Ip Dev Ltd | Treatment paradigm |
| WO2018225063A1 (en) * | 2017-06-04 | 2018-12-13 | Rappaport Family Institute For Research In The Medical Sciences | Method of predicting personalized response to cancer treatment with immune checkpoint inhibitors and kits therefor |
| AU2018345751A1 (en) | 2017-10-02 | 2020-05-07 | Humanigen, Inc. | Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist |
| US10927168B2 (en) * | 2017-10-02 | 2021-02-23 | Humanicen, Inc. | Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab |
| CN113164520A (zh) * | 2018-09-10 | 2021-07-23 | 赫曼尼根公司 | 使用gm-csf拮抗剂治疗免疫疗法相关毒性的方法 |
-
2020
- 2020-06-03 US US17/616,307 patent/US20220331425A1/en not_active Abandoned
- 2020-06-03 EP EP20747245.7A patent/EP3976080A1/en not_active Withdrawn
- 2020-06-03 CN CN202080054412.7A patent/CN114599398A/zh active Pending
- 2020-06-03 CN CN202410532037.2A patent/CN118949031A/zh active Pending
- 2020-06-03 KR KR1020217043260A patent/KR20220042067A/ko not_active Ceased
- 2020-06-03 JP JP2021571692A patent/JP2022535062A/ja active Pending
- 2020-06-03 WO PCT/US2020/035957 patent/WO2020247521A1/en not_active Ceased
- 2020-06-03 AU AU2020287327A patent/AU2020287327A1/en active Pending
-
2024
- 2024-11-08 JP JP2024195743A patent/JP2025013608A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022535062A5 (https=) | ||
| Bando et al. | Preoperative chemoradiotherapy plus nivolumab before surgery in patients with microsatellite stable and microsatellite instability–high locally advanced rectal cancer | |
| Chow et al. | Clinical implications of T cell exhaustion for cancer immunotherapy | |
| Liu et al. | Risk factors for immune-related adverse events: what have we learned and what lies ahead? | |
| Kohrt et al. | Targeting CD137 enhances the efficacy of cetuximab | |
| Di Giacomo et al. | Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study | |
| Cohen et al. | A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors | |
| Stein et al. | Blinatumomab for acute lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation | |
| Liu et al. | The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4 | |
| Wang et al. | Decitabine enhances lymphocyte migration and function and synergizes with CTLA-4 blockade in a murine ovarian cancer model | |
| CN106573977B (zh) | 针对ceacam1的人源化抗体 | |
| US20170044265A1 (en) | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 | |
| JP2020193210A5 (https=) | ||
| JP2022532490A5 (https=) | ||
| JP2020529469A5 (https=) | ||
| CN113396230A (zh) | 癌症的诊断和治疗方法 | |
| Duong et al. | T cell Immunoglobulin and mucin domain containing protein 3 (TIM-3) inhibitors in oncology clinical trials: a review | |
| US9772327B2 (en) | Initial relative lymphocyte count as predictive biomarker | |
| Cohen et al. | Therapeutic combinations of immune-modulating antibodies in melanoma and beyond | |
| JP2023546657A5 (https=) | ||
| TWI828626B (zh) | 併用包含溶血性鏈球菌之菌體的製劑的療法 | |
| JP2020529018A (ja) | チェックポイント阻害薬のための予測末梢血バイオマーカー | |
| Naing et al. | First-in-human phase I study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of PF-07209960 in patients with advanced or metastatic solid tumors | |
| WO2022248478A1 (en) | Compositions and methods for treating lung cancer | |
| Salkeni et al. | Resistance to immunotherapy: mechanisms and means for overcoming |